



## ■ KNEE

# Meaningful values of the EQ-5D-3L in patients undergoing primary knee arthroplasty

**L. Z. Yapp,  
C. E. H. Scott,  
C. R. Howie,  
D. J. MacDonald,  
A. H. R. W. Simpson,  
N. D. Clement**

*From Royal Infirmary of  
Edinburgh, Edinburgh,  
UK*

## Aims

The aim of this study was to report the meaningful values of the EuroQol five-dimension three-level questionnaire (EQ-5D-3L) and EuroQol visual analogue scale (EQ-VAS) in patients undergoing primary knee arthroplasty (KA).

## Methods

This is a retrospective study of patients undergoing primary KA for osteoarthritis in a university teaching hospital (Royal Infirmary of Edinburgh) (1 January 2013 to 31 December 2019). Pre- and postoperative (one-year) data were prospectively collected for 3,181 patients (median age 69.9 years (interquartile range (IQR) 64.2 to 76.1); females, n = 1,745 (54.9%); median BMI 30.1 kg/m<sup>2</sup> (IQR 26.6 to 34.2)). The reliability of the EQ-5D-3L was measured using Cronbach's alpha. Responsiveness was determined by calculating the anchor-based minimal clinically important difference (MCID), the minimal important change (MIC) (cohort and individual), the patient-acceptable symptom state (PASS) predictive of satisfaction, and the minimal detectable change at 90% confidence intervals (MDC-90).

## Results

The EQ-5D-3L demonstrated good internal consistency with an overall Cronbach alpha of 0.75 (preoperative) and 0.88 (postoperative), respectively. The MCID for the Index score was 0.085 (95% confidence interval (CI) 0.042 to 0.127) and EQ-VAS was 6.41 (95% CI 3.497 to 9.323). The MIC<sub>COHORT</sub> was 0.289 for the EQ-5D and 5.27 for the EQ-VAS. However, the MIC<sub>INDIVIDUAL</sub> for both the EQ-5D-3L Index (0.105) and EQ-VAS (-1) demonstrated poor-to-acceptable reliability. The MDC-90 was 0.023 for the EQ-5D-3L Index and 1.0 for the EQ-VAS. The PASS for the postoperative EQ-5D-3L Index and EQ-VAS scores predictive of patient satisfaction were 0.708 and 77.0, respectively.

## Conclusion

The meaningful values of the EQ-5D-3L Index and EQ-VAS scores can be used to measure clinically relevant changes in health-related quality of life in patients undergoing primary KA.

**Cite this article:** *Bone Joint Res* 2022;11(9):619–628.

**Keywords:** EQ-5D, Quality of life, Knee, Osteoarthritis, Arthroplasty

## Article focus

■ To report the meaningful values of the EuroQol five-dimension three-level questionnaire (EQ-5D-3L) Index and EuroQol visual analogue scale (EQ-VAS) scores in patients undergoing primary knee arthroplasty.

## Key messages

■ The EQ-5D-3L was found to be a reliable measure of health-related quality of life

in patients undergoing primary knee arthroplasty (KA), with high levels of internal consistency observed.

■ The minimal clinically important difference for the EQ-5D-3L Index score was 0.085 (95% confidence interval (CI) 0.042 to 0.127) and for the EQ-VAS score was 6.41 (95% CI 3.497 to 9.323).

■ The patient-acceptable symptom state predictive of postoperative satisfaction

Correspondence should be sent to  
Liam Z. Yapp; email:  
liam.yapp@nhs.scot

doi: 10.1302/2046-3758.119.BJR-  
2022-0054.R1

*Bone Joint Res* 2022;11(9):619–  
628.

was 0.708 for the EQ-5D-3L Index score and 77.0 for the EQ-VAS.

### Strengths and limitations

- Comprehensive summary of the meaningful values of the EQ-5D-3L in patients undergoing primary KA for osteoarthritis.
- Focusing on the summary values of the EQ-5D-3L such as the Index and EQ-VAS scores may obscure useful information derived from the health profile data.

### Introduction

Healthcare systems have finite resources, which necessitates prioritization. It is therefore expected that competing interventions demonstrate effectiveness in terms of patient outcomes and costs to the health service. The quality-adjusted life year (QALY) is a measure designed to capture the impact of a treatment on a patient's duration of life and their associated health-related quality of life (HRQoL).<sup>1</sup> QALYs are generated using health utilities, often termed HRQoL weights, which can equate to desirability or value.

The National Institute for Health and Care Excellence (NICE) currently recommends using the EuroQol five-dimension questionnaire (EQ-5D) to measure HRQoL when assessing an intervention's cost-effectiveness (cost-utility analysis).<sup>2</sup> The EQ-5D – developed by the EuroQol Group – is a widely used measure of HRQoL.<sup>3</sup> It is weighted according to the relative importance that specific populations place on different types of health problems. The EQ-5D is often described as 'generic' because it is used to measure HRQoL in a way that can be compared across different patient populations, diseases, and treatments. The UK version of the EQ-5D generates a numerical score (index) and follows the HRQoL convention whereby 1 is considered full health and 0 death, although negative scores are possible with a scoring range of -0.594 to 1.

Two versions of the EQ-5D score are available: with three (3 L) or five (5 L) levels of severity. Critics of the EuroQol five-dimension three-level questionnaire (EQ-5D-3L) argue that it is prone to ceiling effects and is therefore less likely to identify clinically meaningful changes in specific conditions.<sup>4</sup> A newer version of the EQ-5D, the EQ-5D-5L, was developed to tackle these issues and is thought to be more sensitive than the EQ-5D-3L.<sup>5</sup> However, concerns regarding the 5L-value sets for the UK have limited its use.<sup>6,7</sup> Current NICE guidance allows the EQ-5D-5L to be used in reference cases, but states that utilities should be mapped to the original EQ-5D-3L.<sup>8,9</sup>

There is increasing scrutiny regarding the evidence base for common orthopaedic procedures, such as primary knee arthroplasty (KA).<sup>10</sup> It is essential that clinically relevant differences between a cohort, or occurring in an individual patient, can be accurately measured. A substantial proportion of patients awaiting total knee arthroplasty (TKA) have been shown to be living in a health state "worse than death" (WTD) with negative EQ-5D indices.<sup>11</sup> Longer waiting times, due to healthcare service disruption following the global COVID-19

pandemic,<sup>12,13</sup> have led to further measurable deterioration in these patients' HRQoL.<sup>14</sup>

Measures of the EQ-5D-3L's responsiveness, such as minimal clinically important difference (MCID), minimal important change (MIC), minimal detectable change (MDC), and the patient-acceptable symptom state (PASS), are poorly defined in patients undergoing primary KA. The EQ-5D-3L is commonly used to measure HRQoL and to perform cost-utility analyses in orthopaedic surgery. Therefore, it is fundamentally important that clinically meaningful values of the EQ-5D are identified in this patient population. The aim of this study was to report the meaningful values of the EQ-5D-3L in patients undergoing primary KA.

### Methods

This is a retrospective study of patients in a large university teaching hospital (Royal Infirmary of Edinburgh) during the period 1 January 2013 to 31 December 2019. Ethical approval was obtained from the Scotland (A) Research Ethics Committee (16/SS/0026). This study is reported in accordance with the COnsensus-based Standards for the selection of health status Measurement Instruments (COSMIN) guidelines for studies on measurement properties of patient-reported outcome measures (PROMs).<sup>15</sup>

**Data collection and questionnaire administration.** Data were collected prospectively and stored in an electronic research database. Preoperatively, patients completed standardized questionnaires upon attendance at the preadmission clinic. Postoperative data were collected at one-year following surgery via a postal questionnaire.

**Participants.** Patients were included in the study if they were undergoing primary KA (either unicompartmental or TKA) for osteoarthritis (OA) during the study period. Patients who did not respond to the questionnaire, had incomplete data, or who underwent surgery for non-OA indications were excluded for the purposes of this study.

During the period of follow-up there were 4,485 patients undergoing primary KA, of whom 3,181 (70.9%) satisfied the inclusion and exclusion criteria of the study (median age 69.9 years (interquartile range (IQR) 64.2 to 76.1); females, 1,745 (54.9%); median BMI 30.1 kg/m<sup>2</sup> (IQR 26.6 to 34.2)).

**EQ-5D-3L.** The EQ-5D-3L is broadly separated into two elements: the first is the EQ-5D health profile in which respondents answer five questions related to the dimensions: Mobility (MO), Self-Care (SC), Usual Activities (UA), Pain and Discomfort (PD), and Anxiety and Depression (AD).

In this version of the EQ-5D, there are three possible levels indicating the degree of impairment ("None" = 1, "Some" = 2, "Extreme" = 3) leading to 243 (3<sup>5</sup>) potential health states. The EQ-5D health state data can be summarized in a variety of ways,<sup>16,17</sup> however the most common is the use of the Index score. The EQ-5D-3L Index score summarizes each possible health state on a numerical scale ranging from -0.594 to 1, where a score of 1 indicates full health, and scores of 0 and less than 0 indicate a state equivalent to being dead and a state WTD, respectively. The Index score is created by applying value sets to the health state data, typically based

**Table 1.** Descriptive summary of EuroQol five-dimension three-level questionnaire components.

Component	Level	Preoperative		Postoperative		Change		p-value*
		N	%	N	%	N	%	
Mobility	1	296	9.3	1,774	55.8	1,478	46.5	< 0.001
	2	2,881	90.6	1,403	44.1	-1,478	-46.5	
	3	4	0.1	4	0.1	0	0.0	
	Problems	2,885	90.7	1,407	44.2	-1,478	-46.5	
Self-care	1	2,517	79.1	2,632	82.7	115	3.6	< 0.001
	2	653	20.5	528	16.6	-125	-3.9	
	3	11	0.4	21	0.7	10	0.3	
	Problems	664	20.9	549	17.3	-115	-3.6	
Usual activities	1	576	18.1	1,630	51.2	1,054	33.1	< 0.001
	2	2,285	71.8	1,441	45.3	-844	-26.5	
	3	320	10.0	110	3.5	-210	-6.6	
	Problems	2,605	81.9	1,551	48.8	-1,054	-33.1	
Pain/discomfort	1	27	0.8	1,267	39.8	1,240	39.0	< 0.001
	2	1,915	60.2	1,750	55.0	-165	-5.2	
	3	1,239	39.0	164	5.2	-1,075	-33.8	
	Problems	3,154	99.2	1,914	60.2	-1,240	-39.0	
Anxiety/depression	1	2,137	67.2	2,535	79.7	398	12.5	< 0.001
	2	956	30.0	593	18.6	-363	-11.4	
	3	88	2.8	53	1.7	-35	-1.1	
	Problems	1,044	32.8	646	20.3	-398	-12.5	

\*Chi-squared test.

upon the country where respondents are based. This is based upon the relative importance a defined population places on different health problems. The use of preference-based weights enables the general population's views on health problems to be accounted for and accepts that variation exists between countries. As this study was performed in Scotland, we used the 'Time Trade Off' (TTO) value set for the UK. The TTO is a direct method used for generating HRQoL weights, based upon the value that individuals place on different health states.<sup>1</sup> The TTO method presents patients with two alternative health states and asks which they would prefer. This method assesses how much time members of the general population would be willing to sacrifice from their life in order to avoid an impaired health state.

The second element of the EQ-5D is a visual analogue scale (VAS), also called the EQ-VAS, on which respondents are asked to rate their overall health from 0 (worst health imaginable) to 100 (best health imaginable). The EQ-VAS is designed to encompass an individual's health beyond the five dimensions covered in the health profile.

**Reliability: internal consistency.** Internal consistency measures how items within a questionnaire are correlated. This is particularly relevant for outcome scores measuring a single underlying construct, such as HRQoL.<sup>18</sup> Internal consistency was measured using Cronbach's alpha. Cronbach's alpha is scored between 0 and 1, with higher numbers reflecting increasing correlation. Good internal consistency was considered to be a Cronbach's alpha between 0.70 to 0.95.<sup>18</sup>

**Responsiveness.** Responsiveness reflects the sensitivity or ability of a PROM to detect clinically important changes over time.<sup>18-20</sup> A clinically important, or meaningful, change can

be described according to the individual patient or the cohort as a whole.

**Effect size: standardized response mean and standardized effect size.** The standardized response mean (SRM) was used to determine the effect size (ES) in independent and paired data. For independent data, the SRM is the ratio of the mean change score and the standard deviation (SD) of the change score.<sup>21</sup> For the paired data, SRM was adjusted using the below formula:<sup>22,23</sup>

$$SRM_{\text{paired}} = (\text{Mean}_{\text{change score}} / \text{SD}_{\text{change score}}) / (\sqrt{2} \times \sqrt{1-r})$$

where r is the correlation coefficient between the pre- and postoperative scores, and the  $\sqrt{2}$  is used to account for the number of measurements.

The standardized effect size (SES) was calculated for each transition level of the anchor question by dividing the change in mean score by the SD of the preoperative score. The greater the SES, the greater the difference between groups and therefore responsiveness. The ES can be interpreted using Cohen's thresholds:<sup>23,24</sup> < 0.20 (Trivial); 0.20 to 0.49 (Small); 0.50 to 0.79 (Medium); and 0.80 to 1.00 (Large).

**Floor and ceiling effects.** Floor and ceiling effects occur when more than 15% of patients achieve the minimum or maximum score, respectively.<sup>18</sup> When present, this results in an inability to discriminate between subjects at extremes of the scale. Floor and ceiling effects suggest limited content validity, reduced overall reliability, and impaired responsiveness.<sup>18</sup>

**Minimal clinically important difference.** The MCID is the smallest change in an outcome measure which patients perceive to be clinically relevant.<sup>25</sup> The MCID can be defined using anchor-based or distribution-based methodology. We




Fig. 1

Density plot (distribution) of EuroQol five-dimension three-level questionnaire (EQ-5D-3L) Index scores: a) change; b) preoperatively; c) postoperatively.




Fig. 2

Density plot (distribution) of EuroQol visual analogue scale (EQ-VAS) scores: a) change; b) preoperatively; c) postoperatively.

chose to define the EQ-5D-3L MCID using anchor-based methods, as it is not affected by the statistical characteristics of the sample and directly incorporates the patient's perspective.

The questionnaire assessed the patient's global rating of change by using an anchor question assessing the patient's satisfaction following surgery ("How satisfied are you with your operated knee?"), and responses were recorded using a five-point Likert scale: "Very satisfied", "Satisfied", "Neither satisfied nor dissatisfied", "Dissatisfied", and "Very dissatisfied".<sup>26</sup> We assessed the credibility of the anchor question for calculating the MCID using the guidelines described by Devji et al.<sup>27</sup> The responses to the five-point Satisfaction anchor question were also grouped into a secondary binary classification of 'Satisfied' (Very Satisfied and Satisfied) and 'Dissatisfied' (Neither satisfied nor dissatisfied, Dissatisfied, and Very dissatisfied) patients.

The MCID was defined as the difference in the mean change within one year for the EQ-5D-3L Index and the EQ-VAS scores in patients responding "Neither satisfied nor dissatisfied" compared to those responding "Satisfied". The MCID is reported with 95% confidence intervals (CIs) of the difference.

**Minimal important change.** The MIC for the cohort ( $MIC_{COHORT}$ ) was defined as the change, relative to preoperative scores, for those patients declaring themselves as

'Satisfied'.<sup>28</sup> Clinically relevant improvement for an individual patient ( $MIC_{INDIVIDUAL}$ ) predictive of satisfaction ('Satisfied' vs 'Dissatisfied') was estimated using receiver operating characteristic (ROC) curve analysis.<sup>29</sup>

**Patient-acceptable symptom state.** The PASS is the postoperative score which can predict a patient declaring their outcome as 'Satisfied'.<sup>30,31</sup> ROC curve analysis was also used to determine the optimal PASS threshold value.

**Minimal detectable change.** The MDC, also known as the smallest real difference,<sup>32</sup> is a distribution-based method which represents the smallest change beyond the measurement error of the EQ-5D-3L. The MDC-90 was calculated by multiplying the standard error of measurement (SEM) by the square root of two (to account for measurement on two occasions) and by a z score giving a 90% confidence level (1.65).<sup>29,32</sup>

**Statistical analysis.** All data handling, cleaning, and statistical analysis was undertaken using RStudio version 1.3.959 (RStudio, USA). The distribution of continuous variables was plotted to assess appropriateness of parametric or non-parametric tests of differences. Differences between pre- and postoperative EQ-5D-3L Index scores were compared using two-sided paired Wilcoxon signed-rank test. Differences between the change in EQ-5D-3L Index scores were measured using independent-samples two-sided *t*-test. Differences between categorical

**Table II.** Summary of the EuroQol five-dimension three-level questionnaire Index scores for the cohort.

Cohort	n	Preoperative			Postoperative			Change		p-value	SRM <sub>p</sub>	SRM <sub>i</sub>	SES	Preoperative (%)		Postoperative (%)	
		Mean (SD)	Median (IQR)	Range	Mean (SD)	Median (IQR)	Range	Mean (SD)	Range					Floor	Ceiling	Floor	Ceiling
Total	3,181	0.426 (0.31)	0.59 (0.16 to 0.69)	-0.594 to 1.0	0.748 (0.26)	0.796 (0.69 to 1.0)	-0.429 to 1.0	0.322 (0.33)	-1.049 to 1.349	< 0.001*	0.83	0.97	1.05	0.03	0.38	0.06	29.8
Very satisfied	1,763	0.447 (0.30)	0.620 (0.16 to 0.69)	-0.394 to 1.0	0.849 (0.19)	0.883 (0.76 to 1.0)	-0.239 to 1.0	0.402 (0.31)	-0.707 to 1.349	< 0.001*	1.11	1.30	1.33	0.00	0.28	0.00	25.9
Satisfied	904	0.413 (0.30)	0.587 (0.10 to 0.69)	-0.240 to 1.0	0.702 (0.21)	0.727 (0.62 to 0.80)	-0.349 to 1.0	0.289 (0.31)	-0.642 to 1.181	< 0.001*	0.80	0.93	0.95	0.00	0.06	0.00	3.40
Neither satisfied nor dissatisfied	285	0.364 (0.32)	0.364 (0.06 to 0.69)	-0.594 to 1.0	0.569 (0.25)	0.620 (0.52 to 0.69)	-0.429 to 1.0	0.205 (0.33)	-1.049 to 1.079	< 0.001*	0.53	0.62	0.64	0.03	0.03	0.00	0.16
Dissatisfied	176	0.379 (0.31)	0.516 (0.09 to 0.69)	-0.349 to 0.800	0.441 (0.32)	0.620 (0.16 to 0.69)	-0.349 to 0.850	0.061 (0.34)	-0.820 to 0.636	0.020*	0.15	0.18	0.20	0.00	0.00	0.00	0.00
Very dissatisfied	53	0.384 (0.31)	0.440 (0.09 to 0.69)	-0.077 to 0.796	0.263 (0.356)	0.225 (-0.02 to 0.62)	-0.429 to 0.814	-0.121 (0.38)	-1.035 to 0.690	0.028*	-0.24	-0.28	-0.34	0.00	0.00	0.00	0.00

\*Paired Wilcoxon signed-rank test.

EQ-5D-3L, EuroQol five-dimension three-level questionnaire; IQR, interquartile range; SD, standard deviation; SES, standardized effect size; SRM, standardized response mean.

**Table III.** Summary of the EuroQol visual analogue scale scores for the cohort.

Cohort	n	Preoperative			Postoperative			Change		p-value	SRM <sub>p</sub>	SRM <sub>i</sub>	SES	Preoperative (%)		Postoperative (%)	
		Mean (SD)	Median (IQR)	Range	Mean (SD)	Median (IQR)	Range	Mean (SD)	Range					Floor	Ceiling	Floor	Ceiling
Total	3,181	70.4 (19.7)	72.0 (60.0 to 85.0)	0 to 100	77.1 (19.1)	80.2 (70 to 90.1)	0 to 100	6.7 (22.9)	-100.0 to 100.0	< 0.001*	0.26	0.29	0.34	0.47	1.92	0.32	4.83
Very satisfied	1,763	72.1 (19.3)	76.9 (60.0 to 89.0)	0 to 100	82.7 (16.4)	89.6 (79.9 to 92.0)	0 to 100	10.6 (22.0)	-100.0 to 100.0	< 0.001*	0.42	0.48	0.55	0.32	1.19	0.13	3.80
Satisfied	904	69.3 (19.8)	70.3 (57.8 to 82.0)	0 to 100	74.5 (18.1)	80.0 (65.8 to 90.0)	0 to 100	5.3 (21.5)	-99.0 to 90.0	< 0.001*	0.21	0.24	0.27	0.10	0.45	0.10	0.80
Neither satisfied nor dissatisfied	285	66.9 (20.3)	70.0 (50.0 to 80.0)	0 to 100	65.7 (19.7)	70.0 (52.0 to 80.0)	1.2 to 100	-1.1 (22.0)	-60.7 to 89.7	0.389*	-0.05	-0.05	-0.06	0.03	0.23	0.00	0.13
Dissatisfied	176	67.7 (19.0)	70.0 (59.0 to 80.0)	9.5 to 100	61.3 (21.2)	61.0 (50.0 to 79.9)	6.0 to 100	-6.4 (25.2)	-80.7 to 59.9	< 0.001*	-0.22	-0.25	-0.34	0.00	0.03	0.00	0.10
Very dissatisfied	53	65.8 (22.4)	70.9 (50.0 to 85.2)	11.2 to 98	57.0 (24.8)	60.0 (39.5 to 79.0)	0 to 99	-8.8 (30.6)	-78.0 to 78.7	0.043*	-0.26	-0.29	-0.40	0.00	0.00	0.03	0.00

\*Paired Wilcoxon signed-rank test.

EQ-5D-3L, EuroQol five-dimension three-level questionnaire; EQ-VAS, EuroQol visual analogue scale; IQR, interquartile range; SD, standard deviation; SES, standardized effect size; SRM, standardized response mean.

variables, such as the EQ-5D-3L dimensions, preoperative and postoperative, were measured using the chi-squared test. A p-value of less than 0.05 was considered statistically significant.

ROC curve analysis was used to determine optimal thresholds in the MIC<sub>INDIVIDUAL</sub> and the postoperative PASS for prediction of patient satisfaction. The precision of these estimates was summarized using sensitivity, specificity, and area under the curve (AUC) with 95% CIs calculated from 2,000 stratified bootstrap replicates. The AUC

may range between 0.5 (no accuracy) and 1.0 (perfect accuracy). Subclassification of AUC values includes: less than 0.7: “Poor”; 0.7 to 0.8: “Acceptable”; 0.8 to 0.9: “Excellent”; and greater than 0.9: “Outstanding”.<sup>33</sup>

**Results**

**Summary of the EQ-5D-3L.** Prior to surgery, patients primarily reported problems in the domains Pain and Discomfort (PD) (n = 3,154(99.2%), Mobility (MO) (n = 2,885 (90.7%)), and Usual Activities (UA) (n = 2,605

### ROC Curve Analysis - MIC EQ-5D-3L & Satisfaction




Fig. 3

Receiver operating characteristic (ROC) curve analysis for minimal important change (MIC) (Individual) predictive of satisfaction: EuroQol five-dimension three-level questionnaire (EQ-5D-3L) Index and EuroQol visual analogue scale (EQ-VAS).

**Table IV.** Cronbach alpha values for the EuroQol five-dimension three-level questionnaire.

EQ-5D-3L	Preoperative	Postoperative
EQ-5D-3L Index	0.750	0.884
Mobility	0.760	0.867
Self-care	0.727	0.878
Usual activities	0.724	0.862
Pain/discomfort	0.701	0.867
Anxiety/depression	0.735	0.881
EQ-VAS	0.733	0.877

EQ-5D-3L, EuroQol five-dimension three-level questionnaire; EQ-VAS, EuroQol visual analogue scale.

(81.9%). Of these patients, the proportion of “Extreme” responses was highest in the PD domain (“I have extreme pain or discomfort”,  $n = 1,239$  (39.0%)), with few respondents reporting an inability to perform their usual activities (UA level 3 ( $n = 320$  (10.0%))) or confinement to bed (MO level 3 ( $n = 4$  (0.1%))). Significant overall improvements in all domains were seen at one-year postoperative, with the greatest levels of improvement seen in the PD, MO, and UA domains (Table I).

The EQ-5D-3L Index and EQ-VAS scores demonstrated a non-normal distribution pre- and postoperative (Figures 1 and 2). The overall median EQ-5D-3L Index (median preoperative 0.590 (IQR 0.16 to 0.69) vs 0.796 (IQR 0.69 to 1.0);  $p < 0.001$ , Wilcoxon signed-rank test) and EQ-VAS (median preoperative 72.0 (IQR 60.0 to 85.0) vs 80.2 (70 to 90.1);  $p < 0.001$ , Wilcoxon signed-rank test) scores significantly increased (improved) at one-year postoperatively.

The majority of patients considered themselves to be either ‘Very Satisfied’ or ‘Satisfied’ ( $n = 2,667$  (83.8%)). The five-level Satisfaction anchor was significantly associated with mean postoperative change in the Index and EQ-VAS scores (Tables II and III). The direction and magnitude of change was associated with outcome; the highest mean change was seen in patients who considered themselves ‘Very Satisfied’ and ‘Satisfied’ while the lowest mean change was seen in patients who considered themselves ‘Neither satisfied nor dissatisfied’, ‘Dissatisfied’, and ‘Very dissatisfied’.

**Internal consistency.** The EQ-5D-3L demonstrated good internal consistency with an overall Cronbach alpha of

**Table V.** Summary of responsiveness measures – MCID, MIC, PASS, and MDC-90.

Responsiveness measure	EQ-5D-3L	
	Index	EQ-VAS
MCID (95% CI)	0.085 (0.042 to 0.127)	6.41 (3.497 to 9.323)
MIC <sub>COHORT</sub>	0.289	5.27
MIC <sub>INDIVIDUAL</sub>	0.105	-1
AUC (95% CI)	0.702 (0.675 to 0.729)	0.662 (0.634 to 0.689)
Sensitivity, %	78.0	76.1
Specificity, %	58.8	50.8
PASS	0.708	77
AUC (95% CI)	0.839 (0.824 to 0.856)	0.750 (0.727 to 0.773)
Sensitivity, %	71.7	76.1
Specificity, %	86.1	50.8
MDC-90	0.023	0.96

AUC, area under the curve; CI, confidence interval; EQ-5D-3L, EuroQol five-dimension three-level questionnaire; EQ-VAS, EuroQol visual analogue scale; MCID, minimal clinically important difference; MDC-90, minimal detectable change at 90% confidence intervals; MIC, minimal important change; PASS, patient-acceptable symptom state.

0.75 (preoperative) and 0.88 (postoperative), respectively (Table IV).

**Responsiveness.** The EQ-5D-3L Index score showed good overall responsiveness, with ‘Large’ ESs seen across the SRM<sub>Paired</sub>, SRM<sub>Independent</sub>, and SES (Table II). In comparison, the EQ-VAS demonstrated only ‘Small’ ESs, suggesting it is less sensitive to change. However, the ESs differed greatly across the 5-level transition question (Table III).

There was no evidence of a floor or ceiling effect from the preoperative EQ-5D-3L Index and EQ-VAS scores. The postoperative EQ-5D-3L Index score demonstrated evidence of a ceiling effect of 29.8%, but had no evidence of a floor effect (0.06%) (Table II). The postoperative EQ-VAS demonstrated no evidence of a floor (0.32%) or ceiling effect (4.83%) (Table III).

Mean improvement in the EQ-5D-3L Index and EQ-VAS scores for those patients declaring themselves as ‘Neither satisfied nor dissatisfied’ (n = 285) and those who reported themselves as ‘Satisfied’ (n = 904) was used to determine the MCID and MIC for a cohort. The MCID for the EQ-5D-3L Index was 0.085 (95% CI 0.042 to 0.127) and EQ-VAS was 6.41 (95% CI 3.497 to 9.323), respectively. The MIC<sub>COHORT</sub> was 0.289 for the EQ-5D and 5.27 for the EQ-VAS. However, the MIC<sub>INDIVIDUAL</sub> for both the Index and EQ-VAS scores demonstrated poor-to-acceptable levels of reliability (Figure 3) (Table V). The MDC-90 was 0.023 for the EQ-5D-3L Index and 1.0 for the EQ-VAS.

The PASS for the postoperative EQ-5D-3L Index and EQ-VAS that were predictive of patient satisfaction were 0.708 and 77.0, respectively (Figure 4). The Index score demonstrated ‘Good’ levels of prediction, whereas the EQ-VAS was only ‘Acceptable’.

## Discussion


This study reports meaningful values for the EQ-5D-3L Index and EQ-VAS scores for patients undergoing primary KA for OA. This can be used to measure MCID between groups, the MIC for a cohort or an individual patient, and

a postoperative score that is predictive of patient satisfaction. The relative strengths of the EQ-5D-3L are that it is easily understood by respondents, simple to complete, and incorporates the patient’s values through preference-based weighting. In the current study, it was found to be a reliable measure of HRQoL in patients undergoing primary KA with high levels of internal consistency observed.

The EQ-5D-3L Index score demonstrated a ‘Large’ ES, suggesting that it is a responsive measure in this patient population. In comparison, the EQ-VAS demonstrated ‘Small’ ESs and appeared to be less sensitive to small changes. These findings are consistent with those reported by Shim and Hamilton,<sup>34</sup> and may simply reflect that the EQ-VAS is a broader measure of the patient’s health. The EQ-VAS declines with increasing age and is worsened by the presence of ‘problems’ in the self-reported health state.<sup>16,35</sup> Previous studies have reported that patients reporting perfect health via the EQ-5D-3L Index score frequently do not report perfect health in the EQ-VAS.<sup>36</sup> Furthermore, it has been shown that the EQ-5D-3L domain Anxiety & Depression has a stronger correlation with EQ-VAS scores, whereas Pain & Disability had the smallest.<sup>16</sup> These findings may limit the utility of the EQ-VAS in the patients undergoing primary KA.

The Index score demonstrated a large postoperative ceiling effect, affecting approximately one in three respondents. Although previous studies of patients undergoing TKA have also demonstrated large ceiling effects,<sup>37</sup> our findings are far smaller than the 84% reported by Giesinger et al.<sup>4</sup> These differences may reflect the fact that both studies were performed in different countries with their own preference weights and values.

In the current study, ceiling effects were observed primarily in patients who considered themselves ‘Very Satisfied’. This is problematic because this subgroup comprised more than half of the cohort. Large ceiling effects limit both the responsiveness and reliability of a PROM, and could potentially lead to underestimation of



Receiver operating characteristic (ROC) curve analysis for patient acceptable symptom state (PASS) predictive of satisfaction: EuroQol five-dimension three-level questionnaire (EQ-5D-3L) Index and EuroQol visual analogue scale (EQ-VAS).

benefit in this patient group.<sup>18</sup> Changes to the EQ-5D, incorporated in the five-level version, have led to considerably lower ceiling effects and may be more sensitive to changes in these patients undergoing primary KA.<sup>38</sup>

There are few estimates for the MCID of the EQ-5D-3L Index, and none for the EQ-VAS, following KA. Walters and Brazier<sup>39</sup> used anchor-based methods using a five-point global rating of change question (“Compared to one year ago, how would you rate your health in general now?”) to calculate a minimal important difference (MID) of 0.121 in 149 patients undergoing TKA for OA. However, this MID may be overestimated due to small sample size, and their calculations were based on differences in the mean change between patients who responded “Somewhat better” and “Somewhat worse”, rather than those who responded “About the same”. Kang<sup>22</sup> used NHS PROMs data to examine the responsiveness of the EQ-5D-3L in 191,379 patients undergoing primary KA at six months post-surgery. Although NHS PROMs data have a follow-up rate of 51.3%,<sup>40</sup> potentially resulting in a response bias, the anchor-based MCID of 0.09 is consistent with the current study’s estimated MCID of 0.085 (95% CI 0.042 to 0.127).

A limitation of the current study is related to the calculation of ‘meaningful’ values and the EQ-5D-3L. The EQ-5D-3L Index scores already encompass a measure of ‘importance’ as defined by a population of patients, based on their preferences for various health states. Therefore, it could be argued that any difference, no matter how small, in the underlying Index value is clinically meaningful, as this reflects the values of the person affected.<sup>16</sup>

A second limitation relates to the methodology of MCID estimation. Anchor-based MCIDs rely on a patient’s self-rating of change. This requires the patient to retrospectively assess the change in their health between two timepoints and may be subject to recall bias. In addition, the wording of the transition question can influence the way patients respond. Clement et al<sup>41</sup> demonstrated that the rate of patient satisfaction following TKA could be influenced by the focus of the question.

Third, focusing on the Index and EQ-VAS scores may obscure useful information derived from the EQ-5D-3L.<sup>16,42</sup> Examining the health profile data, the current study observed that patients were primarily affected in the domains Pain and Discomfort, Usual

Activities, and Mobility. However, while 90.7% (n = 2,885) of patients recorded problems with Mobility, less than 1% (n = 4) recorded the most extreme level of problems with this domain (“I am confined to bed”). Similar limitations in the response categories for Mobility have previously been identified in patients undergoing total hip arthroplasty.<sup>43</sup> This has implications for how patients undergoing primary KA can describe their health using the EQ-5D-3L, and suggests that only small improvements in the Mobility domain are likely to be detected.

Finally, the pre- and postoperative EQ-5D-3L Index scores demonstrated a non-normal distribution (Figures 1 and 2). This appearance has been noted previously in different health conditions and patient populations summarized by the EQ-5D-3L.<sup>16,44,45</sup> This has led to concerns that this appearance is a construct issue of the questionnaire rather than defining two separate patient clusters. Parkin et al<sup>42</sup> examined this phenomenon, concluding that these patterns arose as a result of the EQ-5D-3L classification system. The presence, and degree, of ‘problems’ (Level 2 or 3) in specific domains leads to recordable differences in patients who had the same conditions. The application of preference-based weights then exacerbates these differences further, as greater value is placed upon level 3 observations thus creating the appearance of two clusters of index scores.<sup>42</sup>

In conclusion, this study reports the clinically meaningful values of the EQ-5D-3L Index and EQ-VAS scores in patients undergoing primary KA for OA. This can be used to measure clinically relevant differences between groups, in individual patients, and may be used to target postoperative scores strongly associated with patient satisfaction. The EQ-5D-3L was found to be reliable and the Index score demonstrated large ESs. However, clinicians should be aware of the presence of postoperative ceiling effects and limitations in the sensitivity of measuring change in specific domains, such as mobility, which could lead to underestimation of benefit in patients undergoing primary KA.

## Twitter

Follow L. Z. Yapp @lzyapp

Follow C. E. H. Scott @EdinburghKnee

## References

- Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. *Br Med Bull*. 2010;96(1):5–21.
- Longworth L, Yang Y, Young T, et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: A systematic review, statistical modelling and survey. *Health Technol Assess*. 2014;18(9):1–224.
- EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. *Health Policy*. 1990;16(3):199–208.
- Giesinger K, Hamilton DF, Jost B, Holzner B, Giesinger JM. Comparative responsiveness of outcome measures for total knee arthroplasty. *Osteoarthritis Cartilage*. 2014;22(2):184–189.
- Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res*. 2011;20(10):1727–1736.
- Hernandez Alava M, Wailoo A, Grimm S, et al. EQ-5D-5L versus EQ-5D-3L: the impact on cost effectiveness in the United Kingdom. *Value Health*. 2018;21(1):49–56.
- Pennington B, Hernandez-Alava M, Pudney S, Wailoo A. The impact of moving from EQ-5D-3L to -5L in NICE technology appraisals. *Pharmacoeconomics*. 2019;37(1):75–84.
- No authors listed. Guide to the methods of technology appraisal 2013. National Institute for Health and Care (NICE). 2013. <https://www.nice.org.uk/process/pmg9/chapter/foreword> (date last accessed 1 August 2022).
- No authors listed. Position statement on use of the EQ-5D-5L value set for England (updated October 2019). National Institute for Health and Care Excellence (NICE). 2019. <https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l> (date last accessed 1 August 2022).
- Blom AW, Donovan RL, Beswick AD, Whitehouse MR, Kunutsor SK. Common elective orthopaedic procedures and their clinical effectiveness: umbrella review of level 1 evidence. *BMJ*. 2021;374(1):1511.
- Scott CEH, MacDonald DJ, Howie CR. “Worse than death” and waiting for a joint arthroplasty. *Bone Joint J*. 2019;101-B(8):941–950.
- Yapp LZ, Clarke JV, Moran M, Simpson A, Scott CEH. National operating volume for primary hip and knee arthroplasty in the COVID-19 era: A study utilizing the Scottish arthroplasty project dataset. *Bone Jt Open*. 2021;2(3):203–210.
- Oussedik S, MacIntyre S, Gray J, McMeekin P, Clement ND, Deehan DJ. Elective orthopaedic cancellations due to the COVID-19 pandemic: where are we now, and where are we heading? *Bone Jt Open*. 2021;2(2):103–110.
- Clement ND, Scott CEH, Murray JRD, Howie CR, Deehan DJ, IMPACT-Restart Collaboration. The number of patients “worse than death” while waiting for a hip or knee arthroplasty has nearly doubled during the COVID-19 pandemic. *Bone Joint J*. 2021;103-B(4):672–680.
- Gagnier JJ, Lai J, Mokkink LB, Terwee CB. COSMIN reporting guideline for studies on measurement properties of patient-reported outcome measures. *Qual Life Res*. 2021;30(8):2197–2218.
- Devlin N, Parkin D, Janssen B. *Methods for Analysing and Reporting EQ-5D Data [Internet]*. Cham: Springer, 2020.
- Devlin NJ, Parkin D, Browne J. Patient-reported outcome measures in the NHS: new methods for analysing and reporting EQ-5D data. *Health Econ*. 2010;19(8):886–905.
- Terwee CB, Bot SDM, de Boer MR, et al. Quality criteria were proposed for measurement properties of health status questionnaires. *J Clin Epidemiol*. 2007;60(1):34–42.
- Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. *J Clin Epidemiol*. 2010;63(7):737–745.
- Guyatt GH, Deyo RA, Charlson M, Levine MN, Mitchell A. Responsiveness and validity in health status measurement: A clarification. *J Clin Epidemiol*. 1989;42(5):403–408.
- Liang MH, Fossel AH, Larson MG. Comparisons of five health status instruments for orthopedic evaluation. *Med Care*. 1990;28(7):632–642.
- Kang S. Assessing responsiveness of the EQ-5D-3L, the Oxford Hip Score, and the Oxford Knee Score in the NHS patient-reported outcome measures. *J Orthop Surg Res*. 2021;16(1):1–12.
- Middel B, van Sonderen E. Statistical significant change versus relevant or important change in (quasi) experimental design: some conceptual and methodological problems in estimating magnitude of intervention-related change in health services research. *Int J Integr Care*. 2002;2(4):e15.
- Cohen J. *Statistical Power Analysis for the Behavioural Sciences*. Second ed. Mahwah, New Jersey: Lawrence Erlbaum Associates, 1988.
- Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertain the minimal clinically important difference. *Control Clin Trials*. 1989;10(4):407–415.
- Rolfson O, Bohm E, Franklin P, et al. Patient-reported outcome measures in arthroplasty registries Report of the Patient-Reported Outcome Measures Working Group of the International Society of Arthroplasty Registries Part II. Recommendations for selection, administration, and analysis. *Acta Orthop*. 2016;87 Suppl 1(362):9–23.
- Devji T, Carrasco-Labra A, Qasim A, et al. Evaluating the credibility of anchor based estimates of minimal important differences for patient reported outcomes: instrument development and reliability study. *BMJ*. 2020;369:m1714.
- Tubach F, Ravaud P, Baron G, et al. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. *Ann Rheum Dis*. 2005;64(1):29–33.
- Beard DJ, Harris K, Dawson J, et al. Meaningful changes for the Oxford hip and knee scores after joint replacement surgery. *J Clin Epidemiol*. 2015;68(1):73–79.

30. **Kvien TK, Heiberg T, Hagen KB.** Minimal clinically important improvement/difference (MCII/MCID) and patient acceptable symptom state (PASS): what do these concepts mean? *Ann Rheum Dis.* 2007;66 Suppl 3(Suppl 3):iii40-1.
31. **Tubach F, Ravaud P, Baron G, et al.** Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. *Ann Rheum Dis.* 2005;64(1):34–37.
32. **Beckerman H, Roebroek ME, Lankhorst GJ, Becher JG, Bezemer PD, Verbeek ALM.** *Qual Life Res.* 2001;10(7):571–578.
33. **Mandrekar JN.** Receiver operating characteristic curve in diagnostic test assessment. *J Thorac Oncol.* 2010;5(9):1315–1316.
34. **Shim J, Hamilton DF.** Comparative responsiveness of the PROMIS-10 Global Health and EQ-5D questionnaires in patients undergoing total knee arthroplasty. *Bone Joint J.* 2019;101-B(7):832–837.
35. **Williams DP, Price AJ, Beard DJ, et al.** The effects of age on patient-reported outcome measures in total knee replacements. *Bone Joint J.* 2013;95-B(1):38–44.
36. **Devlin NJ, Hansen P, Selai C.** Understanding health state valuations: A qualitative analysis of respondents' comments. *Qual Life Res.* 2004;13(7):1265–1277.
37. **Conner-Spady BL, Marshall DA, Bohm E, et al.** Reliability and validity of the EQ-5D-5L compared to the EQ-5D-3L in patients with osteoarthritis referred for hip and knee replacement. *Qual Life Res.* 2015;24(7):1775–1784.
38. **Feng Y, Devlin N, Herdman M.** Assessing the health of the general population in England: how do the three- and five-level versions of EQ-5D compare? *Health Qual Life Outcomes.* 2015;13(1):171.
39. **Walters SJ, Brazier JE.** Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. *Qual Life Res.* 2005;14(6):1523–1532.
40. **No authors listed.** Provisional Patient Reported Outcome Measures (PROMs) in England for Hip and Knee Replacement Procedures (April 2019 to March 2020). NHS Digital. 2020. <https://digital.nhs.uk/data-and-information/publications/statistical/patient-reported-outcome-measures-proms/hip-and-knee-replacement-procedures-april-2019-to-march-2020> (date last accessed 1 August 2022).
41. **Clement ND, Bardgett M, Weir D, Holland J, Gerrand C, Deehan DJ.** The rate and predictors of patient satisfaction after total knee arthroplasty are influenced by the focus of the question: A standard satisfaction question is required. *Bone Joint J.* 2018;100-B(6):740–748.
42. **Parkin D, Devlin N, Feng Y.** What determines the shape of an EQ-5D Index distribution? *Med Decis Making.* 2016;36(8):941–951.
43. **Oppe M, Devlin N, Black N.** Comparison of the underlying constructs of the EQ-5D and Oxford Hip Score: implications for mapping. *Value Health.* 2011;14(6):884–891.
44. **Brazier JE, Harper R, Munro J, Walters SJ, Snaith ML.** Generic and condition-specific outcome measures for people with osteoarthritis of the knee. *Rheumatology (Oxford).* 1999;38(9):870–877.
45. **Jin X, Al Sayah F, Ohinmaa A, Marshall DA, Smith C, Johnson JA.** The EQ-5D-5L is superior to the -3L version in measuring health-related quality of life in patients awaiting THA or TKA. *Clin Orthop Relat Res.* 2019;477(7):1632–1644.

#### Author information:

- L. Z. Yapp, BMSc (Hons), MBChB, MRCSed, Specialty Registrar in Orthopaedics
- C. E. H. Scott, MD, MSc, BSc, FRCSEd(Tr&Orth), MFSTEd, Consultant Orthopaedic Surgeon and NRS Clinical Research Fellow
- C. R. Howie, FRCSEd(Tr&Orth), FRCS(Glas), Consultant Orthopaedic Surgeon
- D. J. MacDonald, BA, MIQA, CQP, Research Associate
- A. H. R. W. Simpson, MA, BCh, DM, FRCS (Ed & Eng), George Harrison-Law Professor of Orthopaedics and Honorary Consultant Orthopaedic Surgeon
- N. D. Clement, PhD, MD, FRCS (Tr&Orth), Consultant Orthopaedic Surgeon Department of Orthopaedics, Division of Clinical and Surgical Sciences, University of Edinburgh, Edinburgh, UK; Department of Trauma & Orthopaedic Surgery, Royal Infirmary of Edinburgh, Edinburgh, UK.

#### Author contributions:

- L. Z. Yapp: Conceptualization, Formal Analysis, Investigation, Methodology, Visualization, Writing – original draft, Writing – review & editing.
- C. E. H. Scott: Formal Analysis, Investigation, Methodology, Supervision, Visualization, Writing – review & editing.
- C. R. Howie: Data curation, Project administration, Resources, Writing – review & editing.
- D. J. MacDonald: Data curation, Project administration, Resources, Writing – review & editing.
- A. H. R. W. Simpson: Data curation, Project administration, Resources, Supervision, Writing – review & editing.
- N. D. Clement: Conceptualization, Formal Analysis, Investigation, Methodology, Supervision, Visualization, Writing – review & editing.

#### Funding statement:

- The authors disclose receipt of the following financial or material support for the research, authorship, and/or publication of this article: financial support from NHS Research Scotland (NRS), through C. E. H. Scott of NHS Lothian.

#### ICMJE COI statement:

- C. R. Howie reports a Vice Chair position on the National Institute for Health and Care Excellence (NICE) Interventional procedures advisory Committee, with no funding or payments received in relation to this study.

#### Acknowledgements:

- The authors thank all orthopaedic surgeons whose patients were included in this study.

#### Ethical review statement:

- Ethical approval was obtained from the Scotland (A) Research Ethics Committee (16/SS/0026).

© 2022 Author(s) et al. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND 4.0) licence, which permits the copying and redistribution of the work only, and provided the original author and source are credited. See <https://creativecommons.org/licenses/by-nc-nd/4.0/>